AstraZeneca (AZ) is to invest a record US$200m in a new manufacturing facility in China. Located in China Medical City (CMC) in Taizhou, Jiangsu province, the plant represents AZ's largest investment in a single manufacturing facility globally. It will produce intravenous and oral solid medicines from the end of 2013. AZ China president Mark Mallon said the firm had been putting down 'deep roots in China for many years' and the new manufacturing facility will provide Chinese patients with high quality medicines that are locally produced.
展开▼
